GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

GeoVax Labs, Inc.

GeoVax Labs, Inc., (NASDAQ: GOVX) is a clinical-stage biotechnology company developing human vaccines against infectious diseases using our Modified Vaccinia Ankara - Virus-Like Particle (MVA-VLP) vaccine platform. 

Our current development programs are focused on vaccines against COVID-19; Hemorrhagic Fever viruses such as Ebola (Zaire, Sudan), Lassa and Marburg; Malaria and Zika virus; and, Human Immunodeficiency Virus (HIV). We have also initiated programs to develop a broadly applicable  immunotherapy against tumor associated antigen MUC1 that is expressed of many solid tumor  types including breast, ovarian, gastric, liver, pancreas, renal and  lymph nodes and immunotherapy to treat human papilloma virus (HPV)-induced cancers. 

For more information, visit www.geovax.com.

Spotlight Content on Pandemic Preparedness: Getting Ready for the Next “Disease X” #vaccines #MVA #pandemic #beprepared $GOVX 

https://buff.ly/3Nt5QI5

GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference.#immunooncology #cancer #headandneckcancer @AHNSinfo @AACRFoundation #aacrAHNS23 $GOVX

https://buff.ly/3NMTCLD

Spotlight Content: "Getting Ready for the Next “Disease X”   #vaccines #COVID19 #immunecompromised #MVA $GOVX
https://buff.ly/3NZEURP

GeoVax has Two (2) products in Phase 2 Clinical Programs.#infectiousdiseases #immunooncology #COVID19 #vaccines #immunocompromised #cancer $GOVX 
https://buff.ly/3J0oCoN

Cancer Immunotherapy Month™ promotes not only general awareness of the field of cancer immunotherapy, but also provides educational growth and professional development opportunities for clinicians, researchers and patients. @sitcancer  #Immunotherapy 
https://buff.ly/44exlff

GeoVax/NIAID rMVA technology raises highly durable vaccine responses #vaccine #manufacturing #MVA #immunotherapies $GOVX 
https://buff.ly/3PGV4hs

Did you Know: Safety for MVA has been demonstrated in more than 120,000 subjects, including immunocompromised individuals. #vaccine #manufacturing #MVA #immunotherapies $GOVX 
https://buff.ly/3PGV4hs

GeoVax's cash runway is sufficient to manage three ongoing Phase 2 clinical programs through the milestones expected to occur over the course of this year. #infectiousdiseases #funding #COVID19 #vaccines #milestones #cancer $GOVX 
https://buff.ly/3Ne0IY0

Project Next Gen is seeking COVID-19 vaccines with enhanced breadth of protection against variants and improved durability. #vaccines #COVID19 #immunecompromised #MVA $GOVX 
https://buff.ly/3Ne0IY0

GeoVax's cash runway is sufficient to managge three ongoing Phase 2 clinical programs through the milestones expected to occur over the course of this year. #infectiousdiseases #funding #COVID19 #vaccines #milestones #cancer $GOVX 
https://buff.ly/3Ne0IY0

NASDAQ:GOVX

GeoVax Labs, Inc.

Last Close

2.69

19/09 20:00

Market Cap

8.09M

Beta: 3.00

Volume Today

676.20K

Avg: 341.24K

PE Ratio

−2.88

PFCF: −0.23

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics